scholarly journals Endotoxin activity assay and polymyxin B hemoperfusion use in a cohort of critically ill patients

Critical Care ◽  
2014 ◽  
Vol 18 (Suppl 1) ◽  
pp. P408
Author(s):  
SL Cutuli ◽  
G De Pascale ◽  
V Alicino ◽  
S Cicconi ◽  
V Di Gravio ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Polymyxin B ◽  
Activity Assay ◽  
Endotoxin Activity Assay ◽  
Endotoxin Activity ◽  
Polymyxin B Hemoperfusion

Endotoxin Activity Assay for the Detection of Whole Blood Endotoxemia in Critically Ill Patients

10.3791/58507 ◽  
2019 ◽  
Author(s):  
Riccardo Pinciroli ◽  
Simone Checchi ◽  
Maurizio Bottiroli ◽  
Gianpaola Monti ◽  
Giampaolo Casella ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Whole Blood ◽  
Activity Assay ◽  
Endotoxin Activity Assay ◽  
Endotoxin Activity

scholarly journals Endotoxin Activity in Patients With Extracorporeal Membrane Oxygenation Life Support: An Observational Pilot Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Chen-Tse Lee ◽  
Chih-Hsien Wang ◽  
Wing-Sum Chan ◽  
Yun-Yi Tsai ◽  
Tzu-Jung Wei ◽  
...  
Keyword(s):  
Pilot Study ◽  
Extracorporeal Membrane Oxygenation ◽  
Clinical Outcomes ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Life Support ◽  
Median Difference ◽  
Endotoxin Activity ◽  
Va Ecmo ◽  
Vv Ecmo

Background: Extracorporeal membrane oxygenation (ECMO) life support has become an integral part of intensive care. The endotoxin activity assay (EAA) is a useful test to measure endotoxemia severity in whole blood. To date, no information is available regarding the EAA levels and their effect on clinical outcomes in critically ill patients with ECMO support.Methods: This prospective observational pilot study enrolled adult critically ill patients with ECMO support from August 2019 to December 2020. The EAA levels were measured within 24 h (T1), and at 25–48 (T2), 49–72 (T3), and 73–96 h (T4) after ECMO initiation. This study primarily aimed to investigate the incidence of high EAA levels (≥0.6) at each time point. Subsequent exploratory analyses were conducted to compare the EAA levels of venoarterial ECMO (VA-ECMO) patients between 30-day survivors and non-survivors. Post-hoc analysis was performed to compare the clinical outcomes of VA-ECMO patients with elevated EAA levels at T3 (vs. T1) and those without elevated EAA levels.Results: A total of 39 VA-ECMO patients and 15 venovenous ECMO (VV-ECMO) patients were enrolled. At T1, the incidence of high EAA level (≥0.6) was 42% in VV-ECMO patients and 9% in VA-ECMO patients (P = 0.02). At T2, the incidence of high EAA level was 40% in VV-ECMO patients and 5% in VA-ECMO patients (P = 0.005). In VA-ECMO patients, EAA levels at T3 were significantly higher in 30-day non-survivors than in survivors (median [interquartile range]: 0.49 [0.37–0.93] vs. 0.31 [0.19–0.51], median difference 0.16 [95% confidence interval [CI], 0.02–0.31]; P = 0.024). Moreover, VA-ECMO patients with elevated EAA levels at T3 (vs. T1) had lower 30-day survival than patients without elevated EAA levels (39 vs. 83%, P = 0.026) and fewer ECMO free days by day 30 (median: 3 vs. 23 days, median difference 12 days [95% CI, 0–22]; P = 0.028).Conclusions: A certain proportion of patients experienced high EAA levels (≥0.6) after VV-ECMO or VA-ECMO initiation. VA-ECMO patients with an elevated EAA level at 49–72 h were associated with poor clinical outcomes.

Severity and prognostic assessment of the endotoxin activity assay in biliary tract infection

2013 ◽  
Vol 21 (2) ◽  
pp. 120-127 ◽  
Author(s):  
Mari Sato ◽  
Ryusei Matsuyama ◽  
Toshiaki Kadokura ◽  
Ryutaro Mori ◽  
Takafumi Kumamoto ◽  
...  
Keyword(s):  
Tract Infection ◽  
Biliary Tract ◽  
Activity Assay ◽  
Biliary Tract Infection ◽  
Endotoxin Activity Assay ◽  
Prognostic Assessment ◽  
Endotoxin Activity

scholarly journals Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens

2013 ◽  
Vol 57 (4) ◽  
pp. 524-531 ◽  
Author(s):  
Ana M. Sandri ◽  
Cornelia B. Landersdorfer ◽  
Jovan Jacob ◽  
Márcio M. Boniatti ◽  
Micheline G. Dalarosa ◽  
...  
Keyword(s):  
Population Pharmacokinetics ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Polymyxin B ◽  
Dosage Regimens ◽  
Selection Of

Evidence and Perspectives on the Use of Polymyxin B-Immobilized Fiber Column Hemoperfusion among Critically Ill Patients

2018 ◽  
pp. 215-222 ◽  
Author(s):  
Chizuru Yamashita ◽  
Kazuhiro Moriyama ◽  
Daisuke Hasegawa ◽  
Yoshitaka Hara ◽  
Naohide Kuriyama ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Polymyxin B

scholarly journals Endotoxin Activity Assay: An Experience of a Southern-Italy Hospital

2014 ◽  
Vol 10 (4) ◽  
pp. 164-166
Author(s):  
Linda Degl’Innocenti ◽  
Flaviano Di Paola ◽  
Rizzo Marianna ◽  
Gerardino Amato
Keyword(s):  
Southern Italy ◽  
Activity Assay ◽  
Endotoxin Activity Assay ◽  
Endotoxin Activity
Sign in / Sign up

Export Citation Format

Share Document